-
Broken String Biosciences Renews Commitment to NIST Genome Editing Consortium, Bolstering Efforts to Standardize Gene Editing Safety
BOSTON & CAMBRIDGE, England–(BUSINESS WIRE)–Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today announced its formal re-engagement as a member of the National Institute of Standards and Technology (NIST) Genome Editing Consortium. Broken String plays a key role in developing the gold-standard of safety testing for gene-editing therapies, based on its INDUCE-seq® platform….
-
Broken String Biosciences Featured in Genetic Engineering News
Quantifying the Breakome By Felix Dobbs, PhD August 1, 2025 Read on GEN Powered by gene editing advances like CRISPR and base editing, cell and gene therapy (CGT) is delivering on the promise of genomic medicine. First-generation CAR T-cell therapies, for example, have been functional cures for many patients with otherwise untreatable hematologic cancers. Newer gene…
-
Steve Becker, Chief Commercial Officer, featured in article considering the key ethical and regulatory considerations in gene editing technologies.
Steve Becker, Chief Commercial Officer, Broken String Biosciences Gene editing therapies have already made a tremendous public impact, most recently with the N-of-1 CRISPR-edited gene therapy that was developed, cleared for clinical use by FDA, and treated a patient in under 8 months. The speed was impressive, but about half of that time was tied to…
